Peggy A. Scherle's most recent trade in Prelude Therapeutics Inc was a trade of 175,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2021 | 6,014 | 27,018 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 26 Aug 2021 | 6,014 | 178,934 | - | 1.4 | 8,600 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.23 per share. | 26 Aug 2021 | 2,707 | 173,527 | - | 36.2 | 98,085 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.32 per share. | 26 Aug 2021 | 2,700 | 176,234 | - | 35.3 | 95,377 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.19 per share. | 26 Aug 2021 | 1,700 | 172,920 | - | 35.2 | 59,819 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2021 | 1,700 | 33,032 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 26 Aug 2021 | 1,700 | 174,620 | - | 1.4 | 2,431 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.08 per share. | 26 Aug 2021 | 607 | 172,920 | - | 37.1 | 22,505 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.07 per share. | 13 Aug 2021 | 2,286 | 172,920 | - | 35.1 | 80,161 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 1,728 | 34,732 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 13 Aug 2021 | 1,728 | 175,206 | - | 1.4 | 2,471 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 558 | 42,672 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 13 Aug 2021 | 558 | 173,478 | - | 1.9 | 1,055 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 20,000 | 36,460 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 27 Jul 2021 | 20,000 | 192,920 | - | 1.4 | 28,600 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.45 per share. | 27 Jul 2021 | 19,320 | 173,600 | - | 35.4 | 684,840 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.09 per share. | 27 Jul 2021 | 680 | 172,920 | - | 36.1 | 24,540 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 95,000 | 95,000 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 07 May 2021 | 10,000 | 182,920 | - | 1.4 | 14,300 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 10,000 | 56,460 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.14 per share. | 07 May 2021 | 5,836 | 173,120 | - | 41.1 | 240,090 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.30 per share. | 07 May 2021 | 3,964 | 178,956 | - | 40.3 | 159,732 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.85 per share. | 07 May 2021 | 200 | 172,920 | - | 41.9 | 8,370 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 4,630 | 66,460 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 08 Apr 2021 | 4,630 | 177,550 | - | 1.4 | 6,621 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.57 per share. | 08 Apr 2021 | 1,669 | 172,920 | - | 39.6 | 66,040 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.97 per share. | 08 Apr 2021 | 1,417 | 176,133 | - | 37.0 | 52,387 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.72 per share. | 08 Apr 2021 | 875 | 175,258 | - | 37.7 | 33,003 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.97 per share. | 08 Apr 2021 | 669 | 174,589 | - | 39.0 | 26,073 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 07 Apr 2021 | 15,370 | 188,290 | - | 1.4 | 21,979 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 15,370 | 71,090 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.02 per share. | 07 Apr 2021 | 8,289 | 180,001 | - | 39.0 | 323,405 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.63 per share. | 07 Apr 2021 | 6,881 | 173,120 | - | 39.6 | 272,679 | Common Stock |
| Prelude Therapeutics Inc | Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.30 per share. | 07 Apr 2021 | 200 | 172,920 | - | 40.3 | 8,060 | Common Stock |